Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)

被引：0
|
作者：
Giagounidis, A. [1 ]
Ades, L. [2 ]
Watts, J. [3 ]
Radinoff, A. [4 ]
Arnan Sangerman, M. [5 ]
Cerrano, M. [6 ]
Font Lopez, P. [7 ]
Zeidner, J. [8 ]
Diez Campelo, M. [9 ,10 ]
Graux, C. [11 ]
Liesveld, J. [12 ]
Selleslag, D. [13 ]
Tzvetkov, N. [14 ]
Fram, R. J. [15 ]
Zhao, D. [15 ]
Bell, J. [15 ]
Friedlander, S. [15 ]
Faller, D. V. [15 ]
Sekeres, M. A. [16 ]
机构：
[1] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany
[2] Hop St Louis, Paris, France
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Hosp Sveti Ivan Rislki, Sofia, Bulgaria
[5] Inst Catala Oncol Inst Invest Biomed Bellvitge ID, Barcelona, Spain
[6] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain
[10] Ctr Canc Res IBMCC USAL CSIC, Salamanca, Spain
[11] Catholic Univ Louvain, Ctr Hosp Univ, Namur, Belgium
[12] Univ Rochester, James P Wilmot Canc Inst, Rochester, NY 14627 USA
[13] AZ Sint Jan Brugge Oostende, Brugge, Belgium
[14] MHAT Dr Georgi Stranski, Clin Haematol, Pleven, Bulgaria
[15] Millennium Pharmaceut Inc, Cambridge, MA USA
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
653
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [41] Results of a Phase II Study of Cladribine, Low Dose Cytarabine and Venetoclax, Alternating with Azacitidine and Venetoclax in Patients with Higher Risk Chronic Myelomonocytic Leukemia or Myelodysplastic Syndromes
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Chien, Kelly S.
    Valero, Yesid Alvarado
    Daver, Naval
    Borthakur, Gautam
    Swaminathan, Mahesh
    Maiti, Abhishek
    Hammond, Danielle E.
    Nogueras-Gonzalez, Graciela
    Huang, Xuelin
    Schneider, Heather
    Shelly, Kristen
    Kadia, Tapan M.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [42] A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).
    Silverman, Lewis R.
    Dohner, Hartmut
    Dombret, Herve
    Mufti, Ghulam J.
    Stone, Richard M.
    Rose, Shelonitda
    Gerike, Torsten
    Camus, Frederic
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Gore, Steven D.
    Skikne, Barry
    Cogle, Christopher R.
    Ning, Yuhong
    MacBeth, Kyle J.
    Laille, Eric
    Ward, M. Renee
    BLOOD, 2009, 114 (22) : 53 - 53
  • [44] Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Fang, Min
    Roulston, Diane
    Bloomfield, Clara D.
    Moseley, Anna
    Nazha, Aziz
    Zhang, Yanming
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal C.
    Cook, Elina K.
    Cull, Alyssa H.
    Rauh, Michael J.
    Appelbaum, Frederick R.
    Erba, Harry P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2745 - +
  • [45] Lemzoparlimab (lemzo) with venetoclax (ven) and/or azacitidine (aza) in patients (pts) with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS): A phase 1b dose escalation study.
    Daver, Naval Guastad
    Stevens, Don A.
    Hou, Jing-Zhou
    Yamauchi, Takahiro
    Moshe, Yakir
    Fong, Chun Yew
    Marzocchetti, Angela
    Adamec, Ryan
    Patel, Maulik
    Lambert, Stacie
    Wu, Kevin
    Rollig, Christoph
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
    Kadia, Tapan M.
    Benton, Christopher
    Erba, Harry P.
    Gandhi, Mitul
    Levy, Moshe Y.
    Percival, Mary-Elizabeth M.
    Ulrickson, Matthew
    Yimer, Habte
    Yu, Min
    Chen, Zi
    Wang, Jing
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2022, 140 : 11659 - 11660
  • [47] Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy
    Platzbecker, Uwe
    Scherres, Winrich
    Guo, Zhenchao
    Calvo, Roser
    Germing, Ulrich
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S233 - S233
  • [48] Enhancing the Content of the EORTC QLQ-C30 to Maximize the Detection of Treatment Benefit in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myeloid Leukemia Using the EORTC Item Bank
    Bell, Jill A.
    Galaznik, Aaron
    Pompilus, Farrah A.
    Strzok, Sara
    Bejar, Rafael
    Fram, Robert J.
    Faller, Douglas V.
    Marquis, Patrick
    BLOOD, 2017, 130
  • [49] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [50] Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML)
    DiPersio, John
    Stadtmauer, Edward A.
    Nademanee, Auaypom P.
    Stiff, Patrick
    Micallef, Ivana
    Angell, J.
    Bridger, G.
    Calandra, Gary
    BLOOD, 2007, 110 (11) : 137A - 137A
12345